The Institute of Cancer Research, London, United Kingdom.
Royal Marsden National Health Service Foundation Trust, London, United Kingdom.
J Clin Oncol. 2019 Feb 1;37(4):305-317. doi: 10.1200/JCO.18.00982. Epub 2018 Dec 11.
IMPORT LOW demonstrated noninferiority of partial-breast and reduced-dose radiotherapy versus whole-breast radiotherapy for local relapse and similar or reduced toxicity at 5 years. Comprehensive patient-reported outcome measures collected at serial time points are now reported.
IMPORT LOW recruited women with low-risk breast cancer after breast-conserving surgery. Patients were randomly assigned to 40 Gy whole-breast radiotherapy (control), 36 Gy whole-breast and 40 Gy partial-breast radiotherapy (reduced-dose), or 40 Gy partial-breast radiotherapy only (partial-breast) in 15 fractions. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires Core 30 and Breast Cancer-Specific Module, Body Image Scale, protocol-specific items, and the Hospital Anxiety and Depression Scale were administered at baseline, 6 months, and 1, 2, and 5 years. Patterns of moderate/marked adverse effects (AEs) were assessed using longitudinal regression models, and baseline predictors were investigated.
A total of 41 of 71 centers participated in the patient-reported outcome measures substudy; 1,265 (95%) of 1,333 patients consented, and 557 (58%) of 962 reported no moderate/marked AEs at 5 years. Breast appearance change was most prevalent and persisted over time (approximately 20% at each time point). Prevalence of breast hardness, pain, oversensitivity, edema, and skin changes reduced over time ( P < .001 for each), whereas breast shrinkage increased ( P < .001). Analysis by treatment group showed average number of AEs per person was lower in partial-breast (incidence rate ratio, 0.77; 95% CI, 0.71 to 0.84; P < .001) and reduced-dose (incidence rate ratio, 0.83; 95% CI, 0.76 to 0.90; P < .001) versus whole-breast group and decreased over time in all groups. Younger age, larger breast size/surgical deficit, lymph node positivity, and higher levels of anxiety/depression were baseline predictors of subsequent AE reporting.
Most AEs reduced over time, with fewer AEs in the partial-breast and reduced-dose groups. Baseline predictors for AE reporting were identified. These findings will facilitate informed discussion and shared decision making for future patients receiving moderately hypofractionated breast radiotherapy.
IMPORT LOW 研究表明,对于局部复发,部分乳房和减剂量放疗与全乳房放疗相比具有非劣效性,且在 5 年内毒性相似或更低。目前报告了在一系列时间点连续收集的综合患者报告结局测量结果。
IMPORT LOW 招募了保乳手术后患有低危乳腺癌的女性患者。患者被随机分配至 40 Gy 全乳房放疗(对照组)、36 Gy 全乳房和 40 Gy 部分乳房放疗(减剂量组)或 15 次分割的 40 Gy 部分乳房放疗(部分乳房组)。在基线、6 个月、1 年、2 年和 5 年时,采用欧洲癌症研究与治疗组织生活质量问卷核心 30 量表和乳腺癌特定模块、体像量表、方案特异性项目和医院焦虑和抑郁量表进行评估。使用纵向回归模型评估中度/重度不良事件(AE)的发生模式,并对基线预测因素进行了研究。
共有 71 个中心中的 41 个参与了患者报告结局测量子研究;1333 例患者中有 1265 例(95%)同意参与,962 例中有 557 例(58%)报告在 5 年内无中度/重度 AE。乳房外观改变最为常见且随时间持续存在(每个时间点约 20%)。乳房硬度、疼痛、超敏反应、水肿和皮肤变化的发生率随时间降低(各因素 P<0.001),而乳房缩小的发生率增加(P<0.001)。按治疗组分析显示,部分乳房组(发生率比,0.77;95%置信区间,0.71 至 0.84;P<0.001)和减剂量组(发生率比,0.83;95%置信区间,0.76 至 0.90;P<0.001)的人均 AE 发生率低于全乳房组,且在所有组中随时间降低。年龄较小、乳房较大/手术缺陷、淋巴结阳性和焦虑/抑郁程度较高是后续 AE 报告的基线预测因素。
大多数 AE 随时间减少,部分乳房和减剂量组的 AE 更少。确定了 AE 报告的基线预测因素。这些发现将有助于为未来接受适度低分割乳房放疗的患者提供知情讨论和共同决策。